|By PR Newswire||
|January 21, 2014 05:00 AM EST||
LOS ANGELES, Jan. 21, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, today announced that two presentations were made last month at the annual American Epilepsy Society meeting held in Washington, DC, which reported positive results using external Trigeminal Nerve Stimulation (eTNS™) for the adjunctive treatment of epilepsy.
In the first presentation, Lina Nashef, M.D., Consultant Neurologist and Honorary Reader at King's College London (KCL) presented a summary of their initial results in the clinical use of NeuroSigma's non-invasive Monarch™ eTNS™ System. Dr. Nashef reported that the treatment was well-tolerated and that there were no serious adverse events. Of the initial 16 patients, 2 patients dropped out early, and in 4 patients it was not possible to evaluate efficacy due to other medication changes or absence seizures that were difficult to count. Of the remaining 10 patients, 6 patients had a 30% or more reduction in seizure frequency and 4 patients had a 50% or more reduction in seizures at the 12-week assessment. In addition, Dr. Nashef reported statistically significant improvements in mood and quality of life. Eight patients chose to continue receiving treatment using the Monarch system beyond the first 18 weeks. These findings were in line with results obtained in the Phase II clinical trial of eTNS for epilepsy at the University of California, Los Angeles (UCLA) and the University of Southern California (USC).
"I am encouraged by these early results and am looking forward to longer follow-up and more patients being offered the device, which we found generally very easy to use. A major advantage is that it is non-invasive," said Dr. Nashef.
"I'm very excited by the results presented by Dr. Nashef and her team in London," commented Christopher DeGiorgio, M.D., Vice President of Neurology at NeuroSigma, Professor of Neurology at UCLA and a co-inventor of eTNS. "These findings are consistent with the clinical trial work we've done in Los Angeles, and further suggest that the benefits of eTNS include not only a reduction in seizures but also an improvement in mood. People with epilepsy have a higher rate of clinically significant depression than the general population, so an easy-to-use treatment that is delivered at home could make a positive impact on the lives of people with epilepsy. Because eTNS is completely non-invasive, one no longer needs to think of neuromodulation as an option only after everything else has failed – eTNS could become the first adjunctive treatment offered," added Dr. DeGiorgio.
In the second presentation, Dr. DeGiorgio reported a summary of the results of a sub-analysis of a previously reported 50-subject Phase II double-blind randomized controlled trial of eTNS in drug resistant epilepsy conducted at UCLA and USC. The sub-analysis included the 26 subjects who met modified inclusion criteria of having between 4 and 60 seizures per month. This is the same inclusion criteria recently approved by the FDA for NeuroSigma's upcoming pivotal trial of eTNS for epilepsy. Using these inclusion criteria, Dr. DeGiorgio reported a statistically significant mean percent change in seizure frequency of ‑34.4% in the eTNS treatment group vs. +6.6% in the control group (p = 0.03).
Background – The Monarch eTNS System from NeuroSigma
In August 2012, NeuroSigma received CE Mark approval to market NeuroSigma's first TNS product, the Monarch™ eTNS™ System in the European Union for the adjunctive treatment of drug-resistant epilepsy (DRE) and major depressive disorder (MDD) for adults and children 9 years and older. In addition, the Monarch™ eTNS™ System also received a Class II medical device license from Health Canada in April of 2013 allowing NeuroSigma to market the system for treatment of DRE and MDD for adults and children 9 years and older. NeuroSigma is currently offering the Monarch™ eTNS™ System to patients in the European Union and Canada with a physician's prescription.
The Monarch™ eTNS™ System is composed of a cell-phone sized pulse generator that delivers electrical signals to the trigeminal nerve, which are transmitted through lead wires to a single-use patch that is applied to the forehead, thereby non-invasively modulating activity in targeted brain regions. Patients may conveniently self-administer the Monarch™ eTNS™ System at home and typically use the device while sleeping.
Background – TNS
The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain, bilaterally and at high frequency. The trigeminal nerve projects to specific areas of the brain, such as the locus coeruleus, nucleus tractus solitarius, thalamus and the cerebral cortex, which are involved in epilepsy, depression, PTSD, ADHD and other disorders.
Trigeminal Nerve Stimulation (TNS) is the electrical stimulation of branches of the trigeminal nerve, which are located near the surface of the forehead. Functional neuroimaging data suggests the mechanism of action of TNS is related to its ability to modulate activity in targeted brain regions.
CAUTION: In the United States, eTNS™ is an investigational device and is limited by Federal (or United States) law to investigational use. The U.S. Food and Drug Administration has given NeuroSigma approval to proceed with a pivotal Phase III clinical trial of eTNS in drug resistant epilepsy. Completion of that Phase III study is necessary before the FDA will consider permitting the marketing and sale of eTNS in the United States.
eTNS, Monarch, and Monarch eTNS are trademarks of NeuroSigma, Inc.
About King's College London
King's College London is one of the oldest and largest colleges of the University of London. King's College Hospital is a large acute-care teaching hospital serving the local diverse community of Lambeth, Southwark, and Lewisham in South London, and features 840 inpatient beds along with a large outpatient program. It also offers tertiary services the clinical neurosciences and other fields to people from a wider catchment area nationally and internationally. Patients come to King's from all over the world – for the skill and compassion of its people and its reputation as pioneers in medical research.
About NeuroSigma, Inc.
NeuroSigma is a Los Angeles-based life sciences company established to develop TNS technologies with the potential to transform medical practice and patients' lives. NeuroSigma is focused on TNS neuromodulation therapies based on intellectual property licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including TNS therapies for epilepsy, depression, post-traumatic stress disorder (PTSD) and attention-deficit hyperactivity disorder (ADHD). For more information about NeuroSigma, please visit www.neurosigma.com.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements, including but not limited to, research and development outcomes, efficacy, adverse reactions, market and product potential, product availability and other statements regarding our eTNS™ system. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include, among other things, general industry and medical device market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new medical device products; inconsistency of treatment results among patients; potential difficulties in manufacturing a new product; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations.
“RackN is a software company and we take how a hybrid infrastructure scenario, which consists of clouds, virtualization, traditional data center technologies - how to make them all work together seamlessly from an operational perspective,” stated Dan Choquette, Founder of RackN, in this SYS-CON.tv interview at @DevOpsSummit at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jan. 24, 2017 04:30 PM EST Reads: 3,660
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
Jan. 24, 2017 04:15 PM EST Reads: 2,729
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
Jan. 24, 2017 02:30 PM EST Reads: 5,918
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Jan. 24, 2017 02:30 PM EST Reads: 5,392
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
Jan. 24, 2017 02:15 PM EST Reads: 3,276
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Jan. 24, 2017 01:45 PM EST Reads: 3,019
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Jan. 24, 2017 01:30 PM EST Reads: 4,497
Discover top technologies and tools all under one roof at April 24–28, 2017, at the Westin San Diego in San Diego, CA. Explore the Mobile Dev + Test and IoT Dev + Test Expo and enjoy all of these unique opportunities: The latest solutions, technologies, and tools in mobile or IoT software development and testing. Meet one-on-one with representatives from some of today's most innovative organizations
Jan. 24, 2017 01:00 PM EST Reads: 1,739
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 7-9, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and E...
Jan. 24, 2017 12:45 PM EST Reads: 5,929
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Jan. 24, 2017 12:30 PM EST Reads: 3,738
“DevOps is really about the business. The business is under pressure today, competitively in the marketplace to respond to the expectations of the customer. The business is driving IT and the problem is that IT isn't responding fast enough," explained Mark Levy, Senior Product Marketing Manager at Serena Software, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Jan. 24, 2017 12:15 PM EST Reads: 11,746
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed ...
Jan. 24, 2017 12:15 PM EST Reads: 6,532
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
Jan. 24, 2017 12:00 PM EST Reads: 2,877
The WebRTC Summit New York, to be held June 6-8, 2017, at the Javits Center in New York City, NY, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 20th International Cloud Expo and @ThingsExpo. WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web co...
Jan. 24, 2017 11:45 AM EST Reads: 3,076
"A lot of times people will come to us and have a very diverse set of requirements or very customized need and we'll help them to implement it in a fashion that you can't just buy off of the shelf," explained Nick Rose, CTO of Enzu, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jan. 24, 2017 10:45 AM EST Reads: 4,837